Trials / Unknown
UnknownNCT06201832
Cardiac Amyloidosis in HFpEF Tunisian Patients
Prevalence of Cardiac Amyloidosis in Heart Failure Patients With Preserved Left Ventricular Ejection Fraction in Tunisia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 87 (estimated)
- Sponsor
- University Tunis El Manar · Academic / Other
- Sex
- All
- Age
- 60 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations. Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis. In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.
Conditions
- Cardiac Amyloidosis
- Heart Failure With Preserved Ejection Fraction
- Echocardiography
- CMR
- Bone Scintigraphy
- Prevalence
- Diagnosis
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2024-07-30
- Completion
- 2024-12-31
- First posted
- 2024-01-11
- Last updated
- 2024-01-17
Locations
1 site across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT06201832. Inclusion in this directory is not an endorsement.